Kezar Life Sciences

Please note: The information displayed on this page might be outdated.
Kezar Life Sciences:
Clinical stage biotechnology company pioneering first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins. The Company is advancing two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition, for the treatment of autoimmune diseases through immune modulation versus direct immunosuppression; and Protein Secretion Inhibition, halting the secretion of target proteins that contribute to a range of cancers and autoimmune diseases. Lead candidate, zetomipzomib (KZR-616), a selective immunoproteasome inhibitor, is being evaluated in Phase 2 clinical trials for lupus nephritis and autoimmune hepatitis, and KZR-261, a first-in-class inhibitor of the Sec61 translocon developed using the Company’s novel discovery Protein Secretion Inhibition Platform, is undergoing a Phase 1 clinical trial for the treatment of advanced/metastatic solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
Suite 300
South San Francisco, CA 94080
United States
More info:
My account:
Company Participants at Solebury 1x1 Management Access Event 2023
- Christopher Kirk, PRESIDENT & CHIEF SCIENTIFIC OFFICER, CO-FOUNDER
- John Fowler, CEO, Co-Founder
- Marc L. Belsky, Chief Financial Officer
- Nick Mordwinkin , PhD, Chief Business Officer
- Noreen Henig, MD, CMO
Top 10 Holders of Kezar Life Sciences Inc
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Avidity Partners Management LP | 9.92 | 6,782,400 | 24.82 | 13F | 12/31/22 |
OrbiMed Advisors LLC | 6.70 | 4,584,322 | 16.78 | 13F | 12/31/22 |
State Street Corp. | 6.22 | 4,253,960 | 15.57 | 13F | 12/31/22 |
Suvretta Capital Management LLC | 5.12 | 3,504,264 | 12.83 | 13F | 12/31/22 |
Bellevue Asset Management AG | 4.43 | 3,031,000 | 11.09 | 13F | 12/31/22 |
Vanguard Group, Inc. (Subfiler) | 4.30 | 2,943,274 | 10.77 | 13F | 12/31/22 |
The Vanguard Group, Inc. | 4.28 | 2,934,996 | 10.74 | Funds | 2/28/23 |
Millennium Management LLC | 4.24 | 2,896,495 | 10.60 | 13F | 12/31/22 |
BlackRock Fund Advisors | 3.66 | 2,504,325 | 9.17 | 13F | 12/31/22 |
CHI Advisors LLC | 2.76 | 1,889,451 | 6.92 | 13F | 12/31/22 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.